Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Therapeutic Advances in Hematology

Volumn 3, Issue 4, 2012, Pages 209-225

  Vaklavas, Christos ^a   Forero Torres, Andres ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

anaplastic large cell lymphoma; antibody drug conjugate; brentuximab vedotin; cAC10 vcMMAE; CD30; CD30 targeting; Hodgkin s lymphoma; SGN 35

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CATHEPSIN B; CD30 ANTIGEN; CD30 LIGAND; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; DOXYCYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEOPHOSMIN; PRALATREXATE; SGN 30; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VEDOTIN; VINBLASTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION REACTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR REGRESSION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84993726247     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712443076     Document Type: Article

References (73)

1. Amakawa R. Hakem A. Kundig T.M. Matsuyama T. Simard J.J. Timms E. et al. (1996) Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84: 55–562.
2. Amin H.M. Lai R. (2007) Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110: 2259–2267.
3. Ansell S.M. Geyer S.M. Maurer M.J. Kurtin P.J. Micallef I.N. Stella P. et al. (2006) Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 12: 6056–6063.
4. Ansell S.M. Horwitz S.M. Engert A. Khan K.D. Lin T. Strair R. et al. (2007) Phase I / II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25: 2764–2769.
5. Bai R. Pettit G.R. Hamel E. (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941–1949.
6. Bartlett N. Grove L.E. Kennedy D.A. Sievers E.L. Forero-Torres A. (2010) Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. J Clin Oncol 28(15 Suppl.): 8062.
7. Bartlett N.L. Younes A. Carabasi M.H. Forero A. Rosenblatt J.D. Leonard J.P. et al. (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111: 1848–1854.
8. Blum K.A. Smith M. Fung H. Zalevsky J. Combs D. Ramies D.A. et al. (2009) Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol 27(15 Suppl.): 8531.
9. Borchmann P. Schnell R. Fuss I. Manzke O. Davis T. Lewis L.D. et al. (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100: 3101–3107.
10. Burroughs L.M. O'Donnell P.V. Sandmaier B.M. Storer B.E. Luznik L. Symons H.J. et al. (2008) Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14: 1279–1287.
11. Cerveny C.G. Law C.L. McCormick R.S. Lenox J.S. Hamblett K.J. Westendorf L.E. et al. (2005) Signaling via the anti-CD30 m Ab SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 19: 1648–1655.
12. Chen R.W. Gopal A.K. Smith S.E. Ansell S.M. Rosenblatt J.D. Savage K.J. et al. (2011) Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). In: J Clin Oncol 29: 8031.
13. Chiarle R. Podda A. Prolla G. Podack E.R. Thorbecke G.J. Inghirami G. (1999) CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 163: 194–205.
14. Corradini P. Tarella C. Zallio F. Dodero A. Zanni M. Valagussa P. et al. (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20: 1533–1538.
15. de Young A.L. Duramad O. Winoto A. (2000) The TNF receptor family member CD30 is not essential for negative selection. J Immunol 165: 6170–6173.
16. Doronina S.O. Toki B.E. Torgov M.Y. Mendelsohn B.A. Cerveny C.G. Chace D.F. et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778–784.
17. Duckett C.S. Thompson C.B. (1997) CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 11: 2810–2821.
18. Duvic M. Reddy S.A. Pinter-Brown L. Korman N.J. Zic J. Kennedy D.A. et al. (2009) A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15: 6217–6224.
19. Edinger J.T. Clark B.Z. Pucevich B.E. Geskin L.J. Swerdlow S.H. (2009) CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 33: 1860–1868.
20. Falini B. Bolognesi A. Flenghi L. Tazzari P.L. Broe M.K. Stein H. et al. (1992) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339: 1195–1196.
21. Fanale M.A. Forero-Torres A. Rosenblatt J.D. Advani R.H. Franklin A.R. Kennedy D.A. et al. (2011) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed / refractory CD30-positive hematologic malignancies. Clin Cancer Res, in press.
22. FDA (2011) ADCETRIS™ (brentuximab vedotin) for injection. Highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf.
23. Fisher R.I. Kaminski M.S. Wahl R.L. Knox S.J. Zelenetz A.D. Vose J.M. et al. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23: 7565–7573.
24. Forero-Torres A. Leonard J.P. Younes A. Rosenblatt J.D. Brice P. Bartlett N.L. et al. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146: 171–179.
25. Francisco J.A. Cerveny C.G. Meyer D.L. Mixan B.J. Klussman K. Chace D.F. et al. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 1458–1465.
26. Gattei V. Degan M. Gloghini A. de Iuliis A. Improta S. Rossi F.M. et al. (1997) CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89: 2048–2059.
27. Gerber H.P. Kung-Sutherland M. Stone I. Morris-Tilden C. Miyamoto J. McCormick R. et al. (2009) Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113: 4352–4361.
28. Horie R. Watanabe T. (1998) CD30: expression and function in health and disease. Semin Immunol 10: 457–470.
29. Huhn M. Sasse S. Tur M.K. Matthey B. Schinkothe T. Rybak S.M. et al. (2001) Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61: 8737–8742.
30. Jemal A. Siegel R. Xu J. Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
31. Katz J. Janik J.E. Younes A. (2011) Brentuximab Vedotin (SGN-35). Clin Cancer Res 17 (20): 6428–6436.
32. Kempf W. Pfaltz K. Vermeer M.H. Cozzio A. Ortiz-Romero P.L. Bagot M. et al. (2011) EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118: 4024–4035.
33. Khan K.D. Emmanouilides C. Benson D.M. Jr. Hurst D. Garcia P. Michelson G. et al. (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 12: 7046–7053.
34. Khouri I.F. Saliba R.M. Hosing C. Okoroji G.J. Acholonu S. Anderlini P. et al. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23: 2240–2247.
35. Kuppers R. (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9: 15–27.
36. Kurts C. Carbone F.R. Krummel M.F. Koch K.M. Miller J.F. Heath W.R. (1999) Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398: 341–344.
37. Kuruvilla J. Keating A. Crump M. (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117: 4208–4217.
38. Lazarus H.M. Rowlings P.A. Zhang M.J. Vose J.M. Armitage J.O. Bierman P.J. et al. (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17: 534–545.
39. Le Gouill S. Milpied N. Buzyn A. de Latour R.P. Vernant J.P. Mohty M. et al. (2008) Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26: 2264–2271.
40. Locksley R.M. Killeen N. Lenardo M.J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487–501.
41. Merkel O. Hamacher F. Sifft E. Kenner L. Greil R. (2011) Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 10: 1127–1136.
42. Milpied N. Fielding A.K. Pearce R.M. Ernst P. Goldstone A.H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14: 1291–1296.
43. Mir S.S. Richter B.W. Duckett C.S. (2000) Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96: 4307–4312.
44. Morschhauser F. Radford J. van Hoof A. Vitolo U. Soubeyran P. Tilly H. et al. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26: 5156–5164.
45. Nadali G. Tavecchia L. Zanolin E. Bonfante V. Viviani S. Camerini E. et al. (1998) Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91: 3011–3016.
46. O'Connor O.A. Pro B. Pinter-Brown L. Bartlett N. Popplewell L. Coiffier B. et al. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29: 1182–1189.
47. Oflazoglu E. Kissler K.M. Sievers E.L. Grewal I.S. Gerber H.P. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142: 69–73.
48. Okeley N.M. Miyamoto J.B. Zhang X. Sanderson R.J. Benjamin D.R. Sievers E.L. et al. (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16: 888–897.
49. Pileri S.A. Zinzani P.L. Gaidano G. Falini B. Gaulard P. Zucca E. et al. (2003) Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma 44(Suppl. 3): S21–S26.
50. Pro B. Advani R. Brice P. Bartlett N. Rosenblatt J.D. Illidge T. et al. (2011) Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 29: 8032.
51. Romagnani P. Annunziato F. Manetti R. Mavilia C. Lasagni L. Manuelli C. et al. (1998) High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91: 3323–3332.
52. Savage K.J. Harris N.L. Vose J.M. Ullrich F. Jaffe E.S. Connors J.M. et al. (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111: 5496–5504.
53. Schmitz N. Pfistner B. Sextro M. Sieber M. Carella A.M. Haenel M. et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359: 2065–2071.
54. Schnell R. Dietlein M. Staak J.O. Borchmann P. Schomaecker K. Fischer T. et al. (2005) Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23: 4669–4678.
55. Schnell R. Staak O. Borchmann P. Schwartz C. Matthey B. Hansen H. et al. (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8: 1779–1786.
56. Sotlar K. Cerny-Reiterer S. Petat-Dutter K. Hessel H. Berezowska S. Mullauer L. et al. (2011) Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 24: 585–595.
57. Staudt L.M. (2010) Oncogenic activation of NF-kappa B. Cold Spring Harb Perspect Biol 2 (6): a000109.
58. Stein H. Mason D.Y. Gerdes J. O'Connor N. Wainscoat J. Pallesen G. et al. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66: 848–858.
59. Sutherland M.S. Sanderson R.J. Gordon K.A. Andreyka J. Cerveny C.G. Yu C. et al. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281: 10540–10547.
60. Teicher B.A. Chari R.V. (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17: 6389–6397.
61. Tian Z.G. Longo D.L. Funakoshi S. Asai O. Ferris D.K. Widmer M. et al. (1995) In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 55: 5335–5341.
62. Vose J. Armitage J. Weisenburger D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124–4130.
63. Wahl A.F. Klussman K. Thompson J.D. Chen J.H. Francisco L.V. Risdon G. et al. (2002) The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 62: 3736–3742.
64. Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin A.S. Jr (1998) NF-kappaB antiapoptosis: induction of TRAF 1 and TRAF 2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683.
65. Witzig T.E. Gordon L.I. Cabanillas F. Czuczman M.S. Emmanouilides C. Joyce R. et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453–2463.
66. Wright C.W. Rumble J.M. Duckett C.S. (2007) CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 282: 10252–10262.
67. Younes A. (2009) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program: 507–519.
68. Younes A. (2011) CD30-targeted antibody therapy. Curr Opin Oncol 23: 587–593.
69. Younes A. Aggarwall B.B. (2003) Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 98: 458–467.
70. Younes A. Bartlett N.L. Leonard J.P. Kennedy D.A. Lynch C.M. Sievers E.L. et al. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363: 1812–1821.
71. Younes A. Carbone A. (1999) CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 14: 135–143.
72. Younes A. Kadin M.E. (2003) Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21: 3526–3534.
73. Zinzani P.L. Pileri S. Bendandi M. Buzzi M. Sabattini E. Ascani S. et al. (1998) Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16: 1532–1537.